The debate over female sexual response has been raging since Masters and Johnson in the 1960's and shows no sign of abating anytime soon. This was made clear during the FDA-approval process of Addyi, a pill for the treatment of Hypoactive Sexual Desire Disorder (HSDD), in 2015. The debate that raged in the media at the time, which included input from political pundits, women's health experts, and HSDD sufferers, both fascinated and infuriated me. For what seemed to be a lifetime, they went back and forth on whether HSDD was a disorder developed by pharmaceutical companies to sell a drug and, even if there was a biological origin, whether it warranted medical therapy. One side of the argument believed that HSDD should only be addressed with cognitive and behavioral therapies rather than drug therapy. The opposing side felt that, due to the multifactorial nature of HSDD, this type of approach wasn't always sufficient and that drug therapy should be one of the tools in a clinician's HSDD treatment arsenal. Unfortunately, the debate in the media took away from the important messages that came out of Addyi's approval - that there was finally an FDA-approved therapy for the most common form of female sexual dysfunction (FSD) and that the FDA pledged to support the development of other safe and effective therapies for FSD.